Rational design, synthesis and biological evaluation of thiadiazinoacridines: A new class of antitumor agents
作者:Ippolito Antonini、Paolo Polucci、Amelia Magnano、Diego Cacciamani、Marek T Konieczny、Jolanta Paradziej-Łukowicz、Sante Martelli
DOI:10.1016/s0968-0896(02)00442-x
日期:2003.2
relevant cytotoxic activity against murine leukemia P388 are reported. The 3-[2-(dimethylamino)ethyl]-6-nitro-2,7-dihydro-3H-2 lambda(4)-thiadiazino[3,4,5-kl]acridin-2-one (12d) has been identified as a new lead in the development of anticancer tetracyclic acridine derivatives.
一系列潜在的与DNA结合的抗肿瘤药,3- [ω-(烷基氨基)烷基] -6-硝基-噻二嗪[3,4,5-kl] ac啶12和1,3-二ω-(烷基氨基)烷基] -6-硝基-噻二嗪[3,4,5-kl] ac啶13是通过用1-[[ω-(烷基氨基)烷基]氨基] -9-亚氨基-4-的SOCl(2)环化制备的硝基-9,10-二氢ac啶16或1-[[ω-(烷基氨基)烷基]氨基] -9- [ω-(烷基氨基)烷基]亚氨基-4-硝基-9,10-二氢ac啶17。已经使用荧光技术检查了12、13的非共价DNA结合特性。描述了这些衍生物对六种肿瘤细胞系的体外细胞毒性潜能,包括人结肠腺癌(HT29)和人卵巢癌(A2780敏感,A2780cisR顺铂耐药,CH1,CH1cisR顺铂耐药和SKOV-3)细胞。与参考药物相比。据报道,某些选定的衍生物具有抗鼠白血病P388的相关细胞毒活性,具有体内抗肿瘤活性。3- [2-(二甲基氨基)乙基]